Accumulated information on biologic prognostic indicators and predictors of response to different types of treatment in patients with different tumor characteristics has made it possible to design clinical protocols on biologic bases. Among cell proliferation indices, the thymidine labelling index (TLI) has proved to be an independent and consistent prognostic indicator over time. Moreover, experimental and retrospective analyses of clinical studies have revealed a direct relation between TLI and response to chemotherapy. On the basis of the results, a prospective clinical protocol on axillary node-negative breast cancer was activated in Italy in 1989.
Methods
Patients with low TLI tumors were treated with local-regional therapy alone, whereas patients with high TLI tumors were randomized to receive local-regional therapy followed or not by adjuvant chemotherapy consisting of 6 cycles of CMF.
Results and Conclusions
The present paper reports on the feasibility of a prospective clinical protocol based on a subgroup of patients with specific pathologic (node negative) and biologic (rapidly proliferating) breast cancers. However, patient eligibility was only 11%.
AdamiH.O., GraffmanS., LindgrenA., SallstromJ.: Prognostic implications of estrogen receptor content in breast cancer.Breast Cancer Res. Treat., 5: 293–300, 1985.
2.
AmadoriD., VolpiA., CalleaA.: Clinical relevance of cell kinetics in breast cancer.Ann. N. Y. Acad. Sci., 698: 186–192, 1994.
3.
AmadoriD., VolpiA., MaltoniR., NanniO., AmaducciL., AmadoriA., Casadei GiunchiD., VioA., SaragoniA., SilvestriniR.: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study.Breast Cancer Res. Treat., 43: 7–14, 1997.
4.
BonettiA., ZaninelliM., RodellaS., MolinoA., SperottoL., PiubelloQ., BonettiF., NortilliR., TurazzaM., CettoG.L.: Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.Breast Cancer Res. Treat., 38: 289–297, 1996.
5.
CatzavelosC., BhattacharyaN., UngY.C., WilsonJ.A., RoncariL., SandhuC., ShawP., YegerH., Morava-ProtznerI., KapustaL., FranssenE., PritchardK.I., SlingerlandJ.M.: Decreased levels of the cell-cycle inhibitor p27kip 1 protein: prognostic implications in primary breast cancer.Nat. Med., 3: 227–230, 1997.
6.
ClarkG.M., DressierL.G., OwensMA., PoundsG., OldakerT., McGuireW.L.: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.NEJM, 320: 627–633, 1989.
7.
Clinical Alert from the National Cancer Institute.Breast Cancer Res.Treat., 12: 3–5, 1988.
8.
ContessoG., MouresseH., FriedmanS., GeninJ., SarrazinD., RouesseJ.: The importance of histologic grade in long-term prognosis of breast cancer.A study of 1010 patients, uniformly treated in the Institute Gustave Roussy. J. Clin. Oncol., 5: 1378–1386, 1987.
9.
Di FronzoG., CoradiniD., CappellettiV., MiodiniP., GranataG., SchwartzM., PankoW.B.: Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels.Anticancer Res., 10: 1690–1706, 1990.
10.
FisherB., CostantinoJ., RedmondC., PoissonR., BowmanD., CoutureJ., DimitrovN.V., WolmarkN., WickerhamD.L., FisherE.R., MargoleseR., RobidouxA., ShibataH., TerzJ., PatersonA.H.G., FeldmanM.I., FarrarW., EvansJ., LickleyH.L., KetnerM.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors.NEJM, 320: 479–484, 1989.
11.
FisherB., FisherE.R., RedmondC., BrownA.: Tumor nuclear grade, estrogen and progesterone receptors: their value alone or in combinations as indicators of outcome following adjuvant therapy for breast cancer.Breast Cancer Res. Treat., 7: 147–160, 1986.
12.
FisherB., RedmondC., DimitrovN.V., BowmanD., Legault-PoissonS., WickerhamD.L., WolmarkN., FisherE.R., MargoleseR., SutherlandC., GlassA., FosterR., CaplanR.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.NEJM, 320: 473–478, 1989.
13.
FisherB., SlarckN., KatrychD., WolmarkN.: Ten-year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy.Surg. Gynecol. Obstet., 140: 528–534, 1975.
14.
GentiliC., SanfilippoO., SilvestriniR.: Cell proliferation and its relationship to clinical features and relapse in breast cancers.Cancer, 48: 974–979, 1981.
15.
HedleyD.W., RuggC.A., NgA.B., TaylorI.W.: Influence of cellular DNA content on disease free survival of stage II breast cancer patients.Cancer Res., 44: 5395–5398, 1984.
16.
HeryM., GioanniC.M., LalanneC.M., NameiM., CourdiA.: The DNA labeling index: a prognostic factor in node-negative breast cancer.Breast Cancer Res. Treat., 9: 207–212, 1987.
17.
KnightW.A., LivingstoneR.B., GregoryE.J., McGuireW.L.: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.Cancer Res., 37: 4669–4671, 1977.
18.
MansourE.G., GrayR., ShatilaA.M., OsborneC.K., TormeyD.C., GilchristK.W., CooperM.R., FalksonG.: Efficacy of adjuvant chemotherapy in high risk node negative breast cancer.NEJM,320: 1989, 485–490, 1989.
19.
MeyerJ.S., FriedmanE., McCrateM.M., BauerW.C.: Prediction of early course of breast carcinoma by thymidine labeling.Cancer, 51: 1879–1886, 1983.
20.
MeyerJ.S., LeeJ.Y.: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness and duration of survival.Cancer Res., 40: 1890–1896, 1980.
21.
MeyerJ.S.: Proliferation assay in prognosis of cancer.J. Clin. Immunoassay, 14: 164–170, 1991.
22.
MeyerJ.S., ProvinceM.: Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.Breast Cancer Res. Treat., 12: 191–204, 1988.
23.
Novaldex Adjuvant Trial Organization:Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years.Br. J. Cancer, 57: 608–611, 1988.
24.
ParadisoA., LorussoV., TommasiS., SchittulliF., MaielloE., De LenaM.: Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer.Breast Cancer Res. Treat., 11: 31–36, 1988.
25.
ParadisoA., MangiaA., BarlettaA., CatinoA.M., GiannuzziA., SchittulliF., RadognaN., LongoS., PalmieriD., MarzulloF., NataleC., TardioB., De LenaM.: Randomized clinical trial of adjuvant chemotherapy in patients with node-negative fast proliferating breast cancer.Drugs,45(Suppl. 2): 68–74, 1993.
26.
ParadisoA., TommasiS., MangiaA., LorussoV., SimoneG., De LenaM.: Tumor-proliferative activity, progesterone receptor status, estrogen receptor level and clinical outcome of estrogen receptor-positive advanced breast cancer.Cancer Res., 50: 2958–2962, 1990.
27.
PestalozziB.C., PetersonH.F., GelberR.D., GoldhirschA., GustersonB.A., TrihiaH., LindtnerJ., Cortes-FinesH., SimmonciniE., ByrneM.J., GolouhR., RudenstamC.M., Castiglione-GertschM., AllegraC.J., JohnstonP.G.: Prognostic importance of thymidylate synthase expression in early breast cancer.J. Clin. Oncol., 15: 1923–1931, 1997.
28.
PiffanelliA., PelizzolaD., GiovanniniG., CatozziL., FaggioliL., GigantiM.: Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies.Tumori, 75: 550–556, 1989.
29.
PorterP.L., MaloneK.E., HeagertyP.J., AlexanderG.M., GattiL.A., FirpoE.J., DalingJ.R., RobertsJ.M.: Expression of cell-cycle regulators p27Kip 1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.Nat. Med., 3: 222–225, 1997.
30.
RemvikosY., BeuzebocP., ZajdelaA., VoillemotN., MagdelenatH., PouillartP.: Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy.J. Natl. Cancer Inst., 81: 1383–7, 1989.
31.
Silvestrini R. and the SICCAB group for quality control of cell kinetic determination.Feasibility and reproducibility of the 3H-TdR labeling index in breast cancer.Cell Prolif., 21: 437–445, 1991.
32.
SilvestriniR., BeniniE., DaidoneM.G., VeneroniS., BoracchiP., CappellettiV., Di FronzoG., VeronesiU.: p53 as an independent prognostic marker in lymph node-negative breast cancer patients.J. Natl. Cancer Inst., 85: 965–970, 1993.
33.
SilvestriniR., DaidoneM.G., BeniniE., FarandaA., TomasicG., BoracchiP., SalvadoriB., VeronesiU.: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.Clin. Cancer Res., 2: 2007–2013, 1996.
34.
SilvestriniR., DaidoneM.G., CostaA.: Cell kinetics of solid tumors with time and its clinical implications.Tumori, 75: 367–372, 1989.
35.
SilvestriniR., DaidoneM.G., Del BinoG., MastoreM., Di FronzoG., BoracchiP.: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers.Ann. Oncol., 4: 13–219, 1993.
36.
SilvestriniR., DaidoneM.G., Di FronzoG., MorabitoA., ValagussaP., BonadonnaG.: Prognostic implications of labeling index versus estrogen receptors and tumor size in node-negative breast cancer.Breast Cancer Res. Treat., 7: 161–169, 1986.
37.
SilvestriniR., DaidoneM.G., LuisiA., BoracchiP., MezzettiM., Di FronzoG., AndreolaS., VeronesiU.: Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer.J. Clin. Oncol, 13: 697–704, 1995.
38.
SilvestriniR., DaidoneM.G., ValagussaP.: Cell kinetics as a prognostic marker in locally advanced breast cancer.Cancer Treat. Rep., 4: 375–379, 1987.
39.
SilvestriniR., DaidoneM.G., ValagussaP., Di FronzoG., MezzanotteG., BonadonnaG.: Cell kinetics as a prognostic indicator in node-negative breast cancer.Eur. J. Cancer Clin. Oncol., 25: 1165–1171, 1989.
40.
SilvestriniR., DaidoneM.G., ValagussaP., Di FronzoG., MezzanotteG., MarianiL., BonadonnaG.: 3H-Thymidine labeling index as a prognostic indicator in node-positive breast cancer.J. Clin. Oncol., 8: 1321–1326, 1990.
41.
SilvestriniR., VeneroniS., DaidoneM.G., BeniniE., BoracchiP., MezzettiM., Di FronzoG., VeronesiU.: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.J. Natl. Cancer Inst., 86: 499–504, 1994.
42.
SkipperH.E.: Kinetic behavior versus response to chemotherapy.N.C.I. Monogr., 34: 2–14, 1971.
43.
StalO., SkoogL., RutqvistL.E., CarstensenJ.M., WingrenS., SullivanS., AnderssonA.C., DufmatsM., NordenskjoldB.: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.Br. J. Cancer,70: 1258–1262, 1994.
44.
SulkesA., LivingstoneR.B., MurphyW.K.: Tritiated thymidine labeling index and response in human breast cancer.J. Natl. Cancer Inst., 62: 513–515, 1979.
45.
TanP., CadyB., WannerM., WorlandP., CukorB., Magi-GalluzziC., LavinP., DraettaG., PaganoM., LodaM.: The cell-cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinoma.Cancer Res., 57: 1259–1263, 1997.
46.
ToikkanenS., HelinH., IsolaJ., JoensuuH.: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.J. Clin. Oncol., 10: 1044–1048, 1992.
47.
TubianaM., CourdiA.: Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival.Radiother. Oncol., 15: 1–18, 1989.
48.
TubianaM., PejovicM.H., ChavaudraN., MalaiseE.P.: The long term prognostic significance of thymidine labelling index in breast cancer.Int. J. Cancer, 33: 441–445, 1984.
49.
TubianaM., PejovicM.H., KoscielnyS., ChavaudraN., MalaiseE.: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer.Int. J. Cancer, 44: 17–22, 1989.
50.
ValagussaP., BonadonnaG., VeronesiU.: Patterns of relapse and survival following radical mastectomy.Cancer, 41: 1170–1178, 1978.
51.
WengerC.R., BeardsleeS., OwensM.A., PoundsG., OldakerT., VendelyP., PandianM.R., HarringonD., ClarkG.M., McGuireW.L.: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.Breast Cancer Res. Treat., 28: 9–20, 1993.
52.
ZambettiM., BonadonnaG., ValagussaP., DaidoneM.G., CoradiniD., BignamiP., ContessoG., SilvestriniR.: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.J. Natl. Cancer Inst. Monogr., 11: 77–83, 1992.
53.
ZambettiM., ValagussaP., BonadonnaG.: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer.Ann. Oncol., 7: 481–485, 1996.
